Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Net Income towards Common Stockholders came in at -$101.4 million in Q1 2026, down 35.42% year-on-year from -$157.1 million in Q1 2025, and down 13.37% quarter-over-quarter from -$89.5 million in Q4 2025.

Scholar Rock Holding (SRRK) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 35.42% year-over-year to -$101.4 million in Q1 2026; TTM through Mar 2026 was -$715.2 million, a 166.34% decrease from a year earlier, with the FY2025 full-year figure at -$377.7 million, down 53.37% from the prior year.
  • Net Income towards Common Stockholders declined to -$101.4 million in Q1 2026 per SRRK's latest filing, from -$89.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$9.2 million in Q1 2022 and bottomed at -$263.8 million in Q2 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$56.8 million (2024), against an average of -$80.2 million.
  • Across the five-year window, Net Income towards Common Stockholders soared 93.69% in 2022 and sank 383.1% in 2023, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$41.8 million in 2022, then fell by 18.96% to -$49.7 million in 2023, then plunged by 36.16% to -$67.7 million in 2024, then sank by 32.26% to -$89.5 million in 2025, then declined by 13.37% to -$101.4 million in 2026.
  • Per Business Quant, the three latest SRRK Net Income towards Common Stockholders figures stand at -$101.4 million (Q1 2026), -$89.5 million (Q4 2025), and -$260.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Scholar Rock Holding 6.32 Bn 6.32 Bn - -101.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -101.45 Mn
Dec 31, 2025 -89.48 Mn
Sep 30, 2025 -260.46 Mn
Jun 30, 2025 -263.83 Mn
Mar 31, 2025 -74.91 Mn
Dec 31, 2024 -67.66 Mn
Sep 30, 2024 -65.66 Mn
Jun 30, 2024 -60.31 Mn
Mar 31, 2024 -56.83 Mn
Dec 31, 2023 -49.69 Mn
Sep 30, 2023 -46.00 Mn
Jun 30, 2023 -42.09 Mn
Mar 31, 2023 -44.43 Mn
Dec 31, 2022 -41.77 Mn
Sep 30, 2022 -46.45 Mn
Jun 30, 2022 -43.90 Mn
Mar 31, 2022 -9.20 Mn
Dec 31, 2021 -35.95 Mn
Sep 30, 2021 -87.69 Mn
Jun 30, 2021 -77.06 Mn